Azeliragon in MGMT Unmethylated Glioblastoma
A phase 2 trial of Azeliragon in glioma & glioblastoma, run by Cantex Pharmaceuticals, active and no longer recruiting.
Overview
Azeliragon in MGMT Unmethylated Glioblastoma is a phase 2 interventional study registered as NCT05986851 by Cantex Pharmaceuticals, with 30 participants enrolled, started 2023-09-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Azeliragon.
Setting
A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma
Phase
Phase 2
Sponsor
Cantex Pharmaceuticals
Registry
Enrolled
30
Similar pages
not linked directly; found by shared links- TrialThe OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Shares Medpace and the tag pipeline.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares Medpace and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Medpace and the tag pipeline.
- TrialMaximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.
- TrialStudy of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Shares Glioma & glioblastoma and the tag pipeline.